E board review in Breast Cancer February 2008 Reading List

Article

html>body {font-size: small;}a:link {color: #990000}a:visited {color: #990000;}a:hover {color: #cccccc}table td {padding: 0pt; border-width: 0; vertical-align: top; font-family: arial, helvetica, verdana, sans-serif;}td#footer {background: #ccffcc; padding: 10px; font: normal 90% arial, helvetica, sans-serif; vertical-align: middle;}td#sponsor a {color: #FFF;}td#sponsor a:visited {color: #FFF;}td#sponsor {background: #333399; width: 625px; height: 10px; padding: 5px; font: 100% verdana, arial, helvetica ; color: #ffffff;}td#date {background: #cccccc; width: 625px; height: 10px; padding: 5px 5px; font: bold 110% verdana, arial, helvetica ; color: #000000;}b#ge {font: italic bold 100% verdana, arial, helvetica;}td#content {font: normal 10pt/14pt arial, verdana, helvetica; padding: 5px;}h3 {font: bold 120% verdana, arial, helvetica, sans-seif; color: #000000; padding: 5px;}h4 {font: normal 120% verdana, arial, helvetica, sans-seif; color: #000000;}h5 {font: times,serif; color: #990000;}div#links {position: absolute; top: 40px left: 0; width: 200px;}div#links a {color: #ffcc00; display: block; padding: 5px 10px; margin: 0 0 2px; border-width=0; text-align: center; font: bold 17px/17px sans-serif; text-decoration: none;}div#links a:visited:hover {color: #cccccc;}a.bluelink:link, a.bluelink:visited { color:#036; font:normal 10px "Lucida Grande", "Lucida Sans Unicode", verdana, lucida, sans-serif; text-decoration :underline;}.menunav { border-top: 2px solid #5A6565; background: #919898; padding: 3px 3px 3px 3px; border-bottom: 2px solid #ffffff; }.menunav_selected { color: #FFFFFF;background: #B2B7B7; border-top: 2px solid #5A6565; padding: 3px 3px 3px 3px; border-bottom: 2px solid #ffffff; }.menunav_selected_sub { background: #D3D6D6; padding: 3px 3px 3px 15px; }div#menu_menu {width: 90%;border: 1px solid #333;padding: 10px 10px 0px 10px;}div#menu_menu a { padding: 3px 0 3px 0; border-top: 1px solid #990000; text-decoration: none;color:#000; font-family:arial, helvetica, sans-serif; font-size: x-small; display: block; text-align: left; vertical-align: bottom;}div#menu_menu a:hover {color: #FFFFFF;background: #990000;}#menu_menu LI { margin: 10; padding: 0; display: inline; border-bottom: 2px solid #ffffff; }div#apply {width: 100%;border: 0px solid #333;padding: 0px 0px 0px 0px;background: #008A45;}div#apply a { border-top: 1px solid #990000; text-decoration: none;color:#FFF0D0; font-family:arial, helvetica, sans-serif; font-size: x-small; display: block; text-align: left; vertical-align: bottom;}div#apply a:hover {color: #FFFFFF;background: #990000;}#apply LI { margin: 10; padding: 0; display: inline; border-bottom: 2px solid #ffffff; } #menurightcolumn { width: 220px; \width: 240px; w\idth: 220px; padding: 10px; text-align: left; margin: 0px; float: right; }.clearer {clear: both;}ol {list-style-type: decimal; margin-left:20px;}

 

Suggested Reading List

Print Entire Reading List

Reducing Risk/Increasing Survival
(Questions 1–7)

Adjuvant Therapy
(Questions 8–13)

Treatment Results
(Questions 14–20)

Advanced and Recurrent Disease
(Questions 21–32)

Breast Cancer Subtypes
(Questions 33–36)

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content